The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.
Randox believes its cash commitment will fill its clinical diagnostics pipeline for years to come, and collaborators include specialists in high-resolution imaging and nanotechnology.
Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.
